Cagrilintide

Cagrilintide research peptide is a novel, long-acting acylated analogue of Amylin (islet amyloid polypeptide). Amylin is a peptide hormone naturally co-secreted with insulin by the pancreatic beta-cells.

While GLP-1 agonists (like GLP1-S) focus on the “incretin” pathway, Cagrilintide targets a completely different mechanism: the Amylin/Calcitonin receptor system. In research models, it permeates the blood-brain barrier to act specifically on the satiety centers of the brainstem (area postrema). It is currently the subject of intense investigation as the perfect “partner” to GLP-1s, with studies suggesting it induces a profound sense of “fullness” and suppression of food-seeking behavior that is distinct from, and additive to, the effects of GLP-1 agonists.

Key Research Applications

• The “CagriSema” Synergy: The most significant application of Cagrilintide is in combination research with GLP1-S (a pairing often referred to in literature as “CagriSema”).

• Glycemic Control: As an amylin analogue, it plays a role in slowing gastric emptying and suppressing postprandial glucagon secretion, which helps smooth out blood sugar spikes after meals without carrying a high risk of hypoglycemia.

⚠️ FOR RESEARCH PURPOSES ONLY This product is intended for laboratory research and development use only. It is not intended for human consumption, diagnostic, or therapeutic use. Handle with care and adhere to all laboratory safety protocols.